Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
5 On Your Side: How to check your credit score is accurate
Recommended
Guide: Amusement parks within driving distance of Raleigh
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
27.72
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,071
Open
27.72
Bid (Size)
29.33 (1)
Ask (Size)
29.36 (12)
Prev. Close
27.72
Today's Range
27.72 - 27.72
52wk Range
26.32 - 42.72
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
NASDAQ:GMAB is showing good growth, while it is not too expensive.
May 02, 2024
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).
Via
Chartmill
Performance
YTD
-13.67%
-13.67%
1 Month
-7.48%
-7.48%
3 Month
-1.60%
-1.60%
6 Month
-0.79%
-0.79%
1 Year
-32.31%
-32.31%
More News
Read More
Decoding 9 Analyst Evaluations For Genmab
April 30, 2024
Via
Benzinga
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Genmab A/S
Via
Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Pfizer Inc.
Via
Business Wire
NASDAQ:GMAB is not too expensive for the growth it is showing.
April 11, 2024
Via
Chartmill
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
Via
Investor's Business Daily
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
April 08, 2024
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
Via
Talk Markets
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
April 03, 2024
Via
Investor's Business Daily
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
April 03, 2024
From
Genmab A/S
Via
Business Wire
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
March 28, 2024
Via
Chartmill
Analyst Ratings For Genmab
March 26, 2024
Via
Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
March 21, 2024
Via
Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
March 05, 2024
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
February 29, 2024
Via
Chartmill
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 27, 2024
From
Genmab A/S
Via
Business Wire
4 Analysts Assess Genmab: What You Need To Know
February 20, 2024
Via
Benzinga
Earnings Outlook For Genmab
February 13, 2024
Via
Benzinga
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
February 08, 2024
Via
Chartmill
Cracking The Code: Understanding Analyst Reviews For Genmab
January 29, 2024
Via
Benzinga
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
February 08, 2024
Via
Chartmill
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024
From
Genmab A/S
Via
Business Wire
What's Going On With Danish Healthcare Firm Genmab Stock?
January 23, 2024
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB.
January 18, 2024
Via
Chartmill
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.